Nova Eye Medical (EYE) Discussion, page-2697

And whilst I say 8-10x is more suitable for a growth stock, you'll find significantly higher multiples often applied for quality growing companies, particularly in the healthcare and tech space. The rerate to a higher valuation multiple alone (not accounting for any actual growth in revenue/earnings) should be quite spectacular when it does arrive. Seems to be an appealing opportunity for both the value investor and the growth investor

Now we just need the numbers to be announced to confirm the conclusions we have made as a result of our observation of industry news-flow and company social media updates!